Association of methionine synthase rs1801394 and methionine synthase reductase rs1805087 polymorphisms with meningioma in adults: A meta‑analysis

Zeng,Xian‑Tao; Lu,Jun‑Ti; Tang,Xiang‑Jun; Weng,Hong; Luo,Jie

doi:10.3892/br.2014.248

Association of methionine synthase rs1801394 and methionine synthase reductase rs1805087 polymorphisms with meningioma in adults: A meta‑analysis

Authors:
- Xian‑Tao Zeng
- Jun‑Ti Lu
- Xiang‑Jun Tang
- Hong Weng
- Jie Luo
View Affiliations

Affiliations: Center for Evidence‑Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: March 12, 2014 https://doi.org/10.3892/br.2014.248
Pages: 432-436

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several epidemiological studies suggested that methionine synthase (MTRR) rs1801394 and methionine synthase reductase (MTR) rs1805087 polymorphisms may be involved in the risk of meningioma in adults; however, the results from different case‑control studies have been inconsistent. Therefore, we performed a meta‑analysis to investigate the association of MTRR and MTR polymorphisms with meningioma. PubMed, Web of Knowledge, China National Knowledge Infrastructure and Wanfang databases were searched up to October 30, 2013 and 3 publications, involving 7 case‑control studies, were finally included. Following data extraction, a meta‑analysis was conducted using Stata 12.0 software. The pooled results based on the fixed effects model demonstrated that the MTRR rs1801394 polymorphism was associated with an increased risk of meningioma [odds ratio (OR)=1.18, 95% confidence interval (CI): 1.05‑1.32 for G vs. A; OR=1.41, 95% CI: 1.12‑1.77 for GG vs. AA; OR=1.08, 95% CI: 0.94‑1.33 for AG vs. AA; OR=1.19, 95% CI: 1.01‑1.40 for (AG+GG) vs. AA; and OR=1.32, 95% CI: 1.07‑1.63 for GG vs. (AG+AA)]; however, an association between the MTR rs1805087 polymorphism and the risk of meningioma was not identified [OR=0.99, 95% CI: 0.88‑1.12 for G vs. A; OR=1.09, 95% CI: 0.80‑1.48 for GG vs. AA; OR=0.95, 95% CI: 0.82‑1.11 for AG vs. AA; OR=0.97, 95% CI: 0.84‑1.13 for (AG+GG) vs. AA; and OR=1.09, 95% CI: 0.80‑1.48 for GG vs. (AG+AA)]. Therefore, the currently available evidence suggests that the MTRR rs1801394 polymorphism may increase the risk of meningioma, whereas the MTRR rs1801394 polymorphism is not associated with meningioma.

View Figures

View References

1	Wiemels J, Wrensch M and Claus EB: Epidemiology and etiology of meningioma. J Neurooncol. 99:307–314. 2010. View Article : Google Scholar
2	Gerber DE, Segal JB, Salhotra A, Olivi A, Grossman SA and Streiff MB: Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis. Cancer. 109:300–305. 2007. View Article : Google Scholar
3	Porter KR, McCarthy BJ, Freels S, Kim Y and Davis FG: Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 12:520–527. 2010. View Article : Google Scholar : PubMed/NCBI
4	Hijiya N, Hudson MM, Lensing S, et al: Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 297:1207–1215. 2007. View Article : Google Scholar : PubMed/NCBI
5	Preston DL, Ron E, Yonehara S, et al: Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst. 94:1555–1563. 2002. View Article : Google Scholar : PubMed/NCBI
6	Ron E, Modan B, Boice JD Jr, et al: Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 319:1033–1039. 1988. View Article : Google Scholar : PubMed/NCBI
7	Sadetzki S, Flint-Richter P, Starinsky S, et al: Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev. 14:969–976. 2005. View Article : Google Scholar : PubMed/NCBI
8	Blitshteyn S, Crook JE and Jaeckle KA: Is there an association between meningioma and hormone replacement therapy? J Clin Oncol. 26:279–282. 2008. View Article : Google Scholar : PubMed/NCBI
9	Lee E, Grutsch J, Persky V, Glick R, Mendes J and Davis F: Association of meningioma with reproductive factors. Int J Cancer. 119:1152–1157. 2006. View Article : Google Scholar : PubMed/NCBI
10	Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P and Feychting M; Swedish Interphone Study Group. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol. 164:629–636. 2006. View Article : Google Scholar : PubMed/NCBI
11	Jhawar BS, Fuchs CS, Colditz GA and Stampfer MJ: Sex steroid hormone exposures and risk for meningioma. J Neurosurg. 99:848–853. 2003. View Article : Google Scholar : PubMed/NCBI
12	Wigertz A, Lönn S, Hall P, et al: Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev. 17:2663–2670. 2008. View Article : Google Scholar : PubMed/NCBI
13	Phillips LE, Koepsell TD, van Belle G, Kukull WA, Gehrels JA and Longstreth WT Jr: History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology. 58:1849–1852. 2002. View Article : Google Scholar : PubMed/NCBI
14	Preston-Martin S, Paganini-Hill A, Henderson BE, Pike MC and Wood C: Case-control study of intracranial meningiomas in women in Los Angeles County, California. J Natl Cancer Inst. 65:67–73. 1980.PubMed/NCBI
15	Inskip PD, Tarone RE, Hatch EE, et al: Cellular-telephone use and brain tumors. N Engl J Med. 344:79–86. 2001. View Article : Google Scholar
16	Johansen C, Boice JD Jr, McLaughlin J and Olsen J: Cellular telephones and cancer - a nationwide cohort study in Denmark. J Natl Cancer Inst. 93:203–207. 2001. View Article : Google Scholar : PubMed/NCBI
17	Rajaraman P, Wang SS, Rothman N, et al: Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 16:1655–1661. 2007. View Article : Google Scholar : PubMed/NCBI
18	Malmer BS, Feychting M, Lönn S, et al: Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 82:229–237. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lai R, Crevier L and Thabane L: Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 14:1784–1790. 2005. View Article : Google Scholar : PubMed/NCBI
20	Olteanu H, Munson T and Banerjee R: Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 41:13378–13385. 2002. View Article : Google Scholar
21	Matsuo K, Suzuki R, Hamajima N, et al: Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood. 97:3205–3209. 2001. View Article : Google Scholar : PubMed/NCBI
22	Yu K, Zhang J, Zhang J, et al: Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet. 18:370–378. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zhang J, Zhou YW, Shi HP, et al: 5,10-Methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTRR), and methionine synthase reductase (MTR) gene polymorphisms and adult meningioma risk. J Neurooncol. 115:233–239. 2013. View Article : Google Scholar : PubMed/NCBI
24	Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 283:2008–2012. 2000. View Article : Google Scholar : PubMed/NCBI
25	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002. View Article : Google Scholar : PubMed/NCBI
26	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
27	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
28	Bethke L, Webb E, Murray A, et al: Functional polymorphisms in folate metabolism genes influence the risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev. 17:1195–1202. 2008. View Article : Google Scholar : PubMed/NCBI
29	Semmler A, Simon M, Moskau S and Linnebank M: Polymorphisms of methionine metabolism and susceptibility to meningioma formation: laboratory investigation. J Neurosurg. 108:999–1004. 2008. View Article : Google Scholar : PubMed/NCBI
30	Xu C, Yuan L, Tian H, Cao H and Chen S: Association of the MTHFR C677T polymorphism with primary brain tumor risk. Tumour Biol. 34:3457–3464. 2013. View Article : Google Scholar : PubMed/NCBI